The Journal of Pediatrics of Korean Medicine (대한한방소아과학회지)

The Association of Korean Oriental Pediatrics (대한한방소아과학회)
권호 표지
DOI QR코드

DOI QR Code

Anti-inflammatory Effect of Sabaek-san Extract through ECS Control in Atopic Dermatitis

아토피피부염에서 ECS 조절을 통한 사백산추출물의 염증 완화 효과

  • Ahn, Sang Hyun (Dept. of anatomy, College of Korean Medicine, Semyung University) ;
  • Jeong, A Ram (Dept. of Pediatrics, College of Korean Medicine, Gachon University) ;
  • Kim, Ki Bong (School of Korean Medicine, Pusan National University)
  • 안상현 (세명대학교 한의과대학 해부학교실) ;
  • 정아람 (가천대학교 한의과대학 소아과학교실) ;
  • 김기봉 (부산대학교 한의학전문대학원)
  • Received : 2022.08.11
  • Accepted : 2022.08.29
  • Published : 2022.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective The purpose of this study was to confirm the effect of Sabaek-san extract on skin damage recovery and inflammation relief in atopic dermatitis-induced mice through Endocannabinoid system (ECS) control. Methods In this study, we used 6-week-old NC/Nga mice were divided into 4 group: control group (Ctrl), lipid barrier elimination group (LBEG), palmitoylethanolamide (PEA) treated group after lipid barrier elimination (PEAG), and Sabaek-san extract treatment group after lipid barrier elimination (SBSG). Each group was assigned 10 animals. After drug administration of three weeks duration following lipid barrier elimination, cannabinoid receptor (CB) 1, CB2, CD (Cluster of Differentiation) 68, phosphorylated inhibitor kappa B (p-IκB), inducible nitric oxide synthase (iNOS), Fc ε receptor, substance P and serotonin were observed to confirm the regulation of the ECS, macrophage activity and mast cell activity. Results We found that 8-hydroxydeoxyguanosine (8-OXdG) positive reaction was significantly lower in the SBST group than in LBET and PEAT groups. Both CB1 and CB2 showed higher positive reactions in the SBST group than in the LBET and PEAT. CD68, p-IκB, iNOS, Fc ε receptor, Substance P and serotonin showed lower positive reaction in the SBST compared to the LBET and PEAT. Conclusion It was confirmed that the Sabaek-san extract can reduce the inflammation of atopic dermatitis by restoring the structural damage of the skin lipid barrier through ECS activity.

Keywords

Acknowledgement

이 연구는 2019년도 정부의 재원으로 한국연구재단의 지원을 받아 수행된 기초연구사업임 (No. NRF2019R1A2C1002443).

References

  1. Kim JH. Current understanding of atopic dermatitis. Pediatr Allergy Respir Dis. 2004;14(1):12-23.
  2. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151-60. https://doi.org/10.1016/S0140-6736(03)12193-9
  3. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, Novak N, Bernstein D, Blessing-Moore J, Khan D, Lang D, Nicklas R, Oppenheimer J, Portnoy J, Randolph C, Schuller D, Spector S, Tilles S, Wallace D. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-9. https://doi.org/10.1016/j.jaci.2012.12.672
  4. Weidinger S, Novak N. Atopic dermatitis. Lancet (London, England). 2016;387(10023):1109-22. https://doi.org/10.1016/S0140-6736(15)00149-X
  5. Zheng T, Yu JH, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):1052242
  6. Jee HM, Kim KW, Kim CS, Sohn MH, Shin DC, Kim KE. Prevalence of asthma, rhinitis and eczema in Korean children using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaires. Pediatr Allergy Respir Dis. 2009;19(2):165-72.
  7. Im GM, Joeng HW, Kim HS, Jeong WY. Oriental medical approach on the allergic disease. Korea J Oriental Physiology & Pathology. 2002;16(5):831-9.
  8. Ahn KM, Kim JH, Kwon HJ, Chae YM, Hahm MI, Lee KJ, Park YM, Lee SY, Han MY, Kim WK. The prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in Korean children: nationwide cross-sectional survey using complex sampling design. J Korean Med Assoc. 2011;54(7):769-78. https://doi.org/10.5124/jkma.2011.54.7.769
  9. Kim MJ, Lee SY. A literature study of atopic dermatitis for children. J Pediatr Korean Med. 2000;14(2):167-82.
  10. Heo J. Donguibogam. 4th ed. Seoul: Namsandang. 1994:145.
  11. Lee DS, Choi HG, Kim KS, Kim DC, Min HK, Li B, Park JH, Oh HC, Kim YC. The comparison between Sabaek-san water and 30% EtOH extracts for anti-inflammatory effects. Yahak Hoeji. 2012;56(4): 240-7.
  12. Ahn SH, Jeong AR, Kim KB. Th2 differentiation control through formation of skin fat barrier of Sabaek-san extract. J Pediatr Korean Med. 2022;36(1):57-64.
  13. Lee HJ. Effects of Sabaek-san on the metrix metalloproteinase-9 in the bronchial asthma mouse model. JPPKM. 2004;18(6):1694-8.
  14. Baron ED, Barzilai D, Johnston G, Kawashima M, Takigawa M, Nakagawa H, Graham-Browh R. Stevens SR. Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, U.S.A. and U.K. Br J Dermatol. 2002;147:710-5. https://doi.org/10.1046/j.1365-2133.2002.04895.x
  15. Kang MY, Jang GT, Kim JH. A study on fetal toxicosis removal therapy. J Pediatr Korean Med. 2003;17(1):29-51.
  16. Lee HJ. Effects of Sabaek-san on the metrix metalloproteinase-9 in the bronchial asthma mouse model. JPPKM. 2004;18(6):1694-8.
  17. Park SH, Park HJ. Root bark extract of Morus alba L. suppressed the migration and invasion of HCT116 human colorectal carcinoma cells. JPPKM. 2021;35(5):177-84. https://doi.org/10.15188/kjopp.2021.10.35.5.177
  18. Korean Medical Pharmacology Text Publication Committee. Korean medical pharmacology. 3rd ed. Seoul: Shinil Books. 2010:116-249.
  19. Salzet M. Invertebrate molecular neuroimmune processes. Brain Res Rev, 2000;34(1):69-79. https://doi.org/10.1016/S0165-0173(00)00041-2
  20. Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev. 2011;63(3):461-70. https://doi.org/10.1124/pr.110.003491
  21. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462. https://doi.org/10.1124/pr.58.3.2
  22. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):669-79. https://doi.org/10.1111/j.1600-0625.2009.00923.x
  23. Luger TA. Neuromediators--a crucial component of the skin immune system. J Dermatol Sci. 2002;30(2):87-93. https://doi.org/10.1016/S0923-1811(02)00103-2
  24. Maccarrone M, Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A. The endocannabinoid system in human keratinocytes: evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003;278(36):33896-903. https://doi.org/10.1074/jbc.M303994200
  25. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007;316(5830):1494-7. https://doi.org/10.1126/science.1142265
  26. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111(1):43-50. https://doi.org/10.1172/JCI200316116
  27. Piazza PV, Lafontan M, Girard J. Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. Diabetes Metab. 2007;33(2):97-107. https://doi.org/10.1016/j.diabet.2007.02.002
  28. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005;168:509-54. https://doi.org/10.1007/3-540-26573-2_17
  29. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol. 2007;152(5):624-32. https://doi.org/10.1038/sj.bjp.0707433
  30. Toth KF, Adam D, Biro T, Olah A. Cannabinoid signaling in the skin: therapeutic potential of the "c(ut)annabinoid" system. Molecules. 2019;24(5):918. https://doi.org/10.3390/molecules24050918
  31. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med. 2002;30(1) Suppl:74-9.
  32. Chung, HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18-30. https://doi.org/10.1016/j.arr.2008.07.002
  33. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87(1):13-20. https://doi.org/10.1016/S0092-8674(00)81318-5
  34. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sciences. 2004;75(6):639-53. https://doi.org/10.1016/j.lfs.2003.10.042
  35. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001;344(1):30-7. https://doi.org/10.1056/NEJM200101043440106